Company intelligence / Profile preview

StemCo Biomedical

Durham, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

StemCo Biomedical was a biotechnology company focused on the identification, isolation, and expansion of specific populations of adult stem cells for therapeutic use. Spun out of Duke University, the company developed a proprietary platform based on the activity of the enzyme aldehyde dehydrogenase (ALDH) to identify highly potent 'ALDHbright' stem cells. These cells were primarily targeted for use in hematopoietic stem cell transplants to improve engraftment and immune reconstitution. The company's technology and assets were acquired by Aldagen in 2003, which continued the development of these cell-based therapies.

Therapeutic areas: OncologyCardiovascularMetabolic Disorders
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Partnerships

Duke University

Beyond the preview

Go deeper on StemCo Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemCo Biomedical.

Explore the full profile